<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048227</url>
  </required_header>
  <id_info>
    <org_study_id>UF9773</org_study_id>
    <nct_id>NCT03048227</nct_id>
  </id_info>
  <brief_title>Can Continuous Glucose Measurements Help Diabetic Patients Treated With an Implantated Pump?</brief_title>
  <acronym>CGMIP</acronym>
  <official_title>Assessement of the Influence of Continuous Glucose Measurement on Glucose Control of Type 1 Diabetic Patients Treated by Implanted Insulin Pump</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During this study, we propose to assess the utility of Continuous Glucose Measurements (CGM)
      in a group of Type 1 diabetic patients treated with an implanted insulin pump. Patients will
      participate in two period of 3 months separated by a 3 months washout. During one period,
      they will use CGM to adapt their insulin therapy while during the other period, they will
      manage their diabetes with their usual capillary blood glucose meter. We except to observe an
      increase of time spent in glucose safe range when using CGM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucose control and quality of life of patients with type 1 diabetes with high glucose
      variability can be improve with use of an implanted pump which delivers insulin by the
      intra-peritoneal route. Some patients however still have difficulties to achieve their
      glycemic goal despite this therapy. Continuous Glucose Measurements (CGM) has proven to be
      able to improve glucose control (HbA1c, time spent in hypoglycaemia) of patients treated with
      an external insulin pump. No trial has been performed yet to assess the utility of CGM on
      patients using an intra-peritoneal insulin delivery.

      During this study, we propose to assess the influence of CGM use on type 1 diabetic subject
      treated with implanted insulin pump. It is a prospective, randomized cross-over study. After
      a 2 weeks run-in period with CGM followed by a 4 weeks break, subjects will participate at
      two experimental periods of 3 months separated with a 3 month washout. During the
      intervention phase, patient will use a CGM system (Abbott Freestyle Navigator II) to adapt
      their insulinotherapy. During the control period, patients will based their insulinotherapy
      upon their usual care and capillary glucose measurements. The order of the periods will be
      randomized.

      The main endpoint will be the time spent in glucose interval 70-180mg/dL during the last 20
      days of each period. The control arm will wear a blinded sensor during this phase to allow
      comparison.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time spent with glucose</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Time spent with glucose between 70-180mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in hypoglycaemia</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Time spent in hypoglycaemia (&lt;70mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in hyperglycemia</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Time spent in hyperglycemia (&gt;180mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in glucose range</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Time spent in glucose range [70-180] and [80-140] mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose mean and standard deviation</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Glucose mean and standard deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Blood Glucose Index (LBGI)</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Low Blood Glucose Index (LBGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Blood Glucose Index (HBGI)</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>High Blood Glucose Index (HBGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Variability</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Glucose Variability: MARD : Mean Absolute Relative Difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Variability</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Glucose Variability: MAGE : Mean Amplitude of Glucose Excursions
-MODD : Mean Of daily blood Glucose Difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Variability</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Glucose Variability: MODD : Mean Of daily blood Glucose Difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of symptomatique hypoglycaemia, severe et non severe</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Number of symptomatique hypoglycaemia, severe et non severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pump programmation</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Number of pump programmation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of sensor use</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Percentage of sensor use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of Quality of Life questionnaire (IDSRQ)</measure>
    <time_frame>last 20 days of intervention period</time_frame>
    <description>Score of Quality of Life questionnaire (IDSRQ)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Continuous Glucose Measurement (CGM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will manage their diabetes as usual as recommended by their care team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Measurement (CGM)</intervention_name>
    <description>Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).</description>
    <arm_group_label>Continuous Glucose Measurement (CGM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 and 70

          -  Type 1 diabetes for at least 1 year

          -  Treatment of diabetes withimplanted insulin pump for at least 6 months

          -  HbA1c level between 7.5 and 10%

          -  Minimum of 4 capillary glucose controls per day over past 3 months

          -  Use of CGM at least 75% during run-in period

          -  Willingness to follow all study procedures

          -  Informed consent signed

          -  Patient must be affiliated or beneficiary of a social medical insurance

        Exclusion Criteria:

          -  Pregnancy of breast feeding, or intention to be pregnant during the study duration

          -  Impaired cognitive or psychological abilities which may result in defective adherence
             to study procedures

          -  Any disease which could make the use glucose sensor difficult (ex : blindness, severe
             arthrosis or immobility)

          -  Known allergy to medical adhesive or glucose sensor component

          -  Medication affecting glucose metabolism, unless stable during the study

          -  Long term use of continuous glucose measurements during pas 6 months

          -  Pump implanted more than 6 years ago

          -  Anti-insulin antobodies syndrom

          -  Active enrollment in another clinical trial or participation in a study within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric RENARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric RENARD, MD</last_name>
    <phone>467338382</phone>
    <phone_ext>33</phone_ext>
    <email>e-renard@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu de Nancy</name>
      <address>
        <city>Nancy</city>
        <state>Vandoeuvre-les-nancy</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno GUERCI</last_name>
      <email>b.guerci@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33078</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BOGDAN CATARGI</last_name>
      <email>bogdan.catargi@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien</name>
      <address>
        <city>Corbeil-essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvia FRANC</last_name>
    </contact>
    <contact_backup>
      <last_name>sylvia.franc@ch-sud-francilien.fr</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>77908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine BAILLOT-RUDONI</last_name>
      <email>sabine.rudoni@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PIERRE FONTAINE</last_name>
      <email>pierre.fontaine@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP - Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paline SCHAEPELYNCK</last_name>
      <email>pauline.schaepelynck@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UHMontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric RENARD, MD</last_name>
      <phone>4 67 33 83 82</phone>
      <phone_ext>33</phone_ext>
      <email>e-renard@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP - Hôpitaux de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Pierre RIVELINE</last_name>
      <email>jeanpierre.riveline@lrb.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie JEANDIDIER</last_name>
      <email>nathalie.jeandidier@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TIDM</keyword>
  <keyword>Type1diabetes</keyword>
  <keyword>Implantable Pump</keyword>
  <keyword>CGM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

